Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Recce Pharmaceuticals Ltd. ( (AU:RCE) ).
Recce Pharmaceuticals has received regulatory and ethics approvals to commence a Phase 3 clinical trial in Indonesia for its RECCE 327 topical gel, targeting diabetic foot infections. This trial, if successful, could pave the way for broader ASEAN region approval. The company also reported a significant A$6.75 million R&D rebate, bolstering its financial position. This rebate, alongside a U.S. Department of Defence grant, highlights Recce’s strategic financial management and its potential impact on further advancing its clinical and pre-clinical projects.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company in the biotechnology industry, focused on developing a new class of synthetic anti-infectives. Its primary product is RECCE 327, a topical gel aimed at treating bacterial infections, with a particular market focus on addressing antimicrobial resistance and infectious diseases in regions like ASEAN.
YTD Price Performance: -4.17%
Average Trading Volume: 135,386
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$106.7M
Learn more about RCE stock on TipRanks’ Stock Analysis page.
